Drug Trial Radar · NCT05656092
A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer
Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
199
Actual
Start
Mar 6, 2023
Primary completion
Dec 19, 2024
Study completion Dec 19, 2024
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Dec 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, double-blind, active-controlled, phase III study to evaluate the efficacy and safety of HIP0612 in patients with gastric ulcer.
Conditions
- Gastric Ulcer
Interventions
HIP0612Drug
Test drug
HPP2202Drug
Placebo drug
RLD2204Drug
Reference drug
HPP2201Drug
Placebo drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Healing rate of gastric ulcerTime frame: week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.